Document:

EX-10.9

 Exhibit 10.9 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if
publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exclusivity Agreement 
 This Exclusivity
Agreement (including all exhibits attached hereto is referred to herein, collectively, as this “Agreement”) is entered into as of August 3, 2018, by and between LumiraDx, Inc., a Delaware corporation
(“LumiraDx”), and CVS Pharmacy, Inc., a Rhode Island corporation (“CVS”). LumiraDx and CVS are each referred to herein by name or, individually, as a “Party” or, collectively, as the
“Parties.” 
 RECITALS 

WHEREAS, LumiraDx has developed proprietary technology for use in the Field (as defined below) which is embodied in the Product (as defined below) 

WHEREAS, CVS has agreed to make an equity investment in LumiraDx Limited, a Cayman Island corporation, a direct parent corporation of LumiraDx
(“Lumira Parent”), pursuant to that certain Preferred Share Subscription Letter agreement (the “Preferred Share Subscription Letter”) dated as of July 17, 2018, by and between CVS and Lumira Parent, and certain
other transaction agreements related thereto; and 
 WHEREAS, in connection with such equity investment, CVS desires to obtain the exclusive right to
purchase and use the Product in the Exclusive Field in the Territory throughout the Exclusivity Period and the non-exclusive right to purchase and use the Product in the Non-Exclusive Field in the Territory throughout the Exclusivity Period. 

WHEREAS, this Agreement shall become effective upon CVS paying the Subscription Amount (as defined in the Preferred Share Subscription Letter) to LumiraDx
Limited by or on the First Closing Date (as defined in the Preferred Share Subscription Letter) (the date of such payment, the “Effective Date”), and otherwise shall have no force or effect. 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 1.     DEFINITIONS. When used in
this Agreement, each of the following terms will have the meaning set forth below (and each such term will have the same meaning whether the singular or plural form is used).  

1.1.     “AAA” is defined in Section 11.2. 

1.2.     “Affiliate” with respect to a particular a Person means any other Person which controls, is
controlled by or is under common control with such Person, where “control,” for purposes of this definition, means (i) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto
any material decision relating to the management or policies of a Person or a majority of the composition of the board of directors (or similar governing body), in each case, whether through the ownership of voting securities, by contract or
otherwise, or (ii) the Beneficial Ownership, directly or indirectly, of at least 50% of the voting securities of a Person. 
 1.3.
    “Agreement” is defined in the Preamble. 

 1.4.     “Applicable Law” means, with respect to the
Parties or the Product in the Territory, all national, federal, state, local, governmental, judicial, arbitral and other laws, statutes, codes, treaties, conventions, rules, regulations, judgments, awards, orders, directives and other pronouncements
having the effect of law or similar binding effect, governing the activities contemplated by this Agreement. 
 1.5.    
“Assigning Party” is defined in Section 12.6. 
 1.6.     “Authorized Third Party
User” means any authorized Third Party appointed by CVS and approved by LumiraDx or any of its Affiliates to use the Product in the Field in the Territory for the Permitted Use. 

1.7.     “Beneficial Ownership” will be determined in accordance with Rule 13d-3 of the Securities
Exchange Act of 1934, as amended. Further, a Person will only be deemed an Affiliate hereunder for so long as such Person satisfies the above definition of an Affiliate. 

1.8.     “Business Day” means a day on which banking institutions in New York, New York, USA are open for
business. 
 1.9.     “Calendar Quarter” means each of the respective periods of three consecutive
calendar months ending on March 31, June 30, September 30 and December 31. 
 1.10.
    “Claiming Party” is defined in Section 9.4. 
 1.11.
    “Commercially Reasonable Efforts” means [***]. 
 1.12.
    “Confidential Information” is defined in Section 5.1. 
 1.13.
    “Consumables” means, with respect to any given Instrument, (a) the Test Strips and (b) and other consumables, in each case as made available by LumiraDx or its Affiliates or licensees for use with
such Instrument. 
 1.14.     “Control”, “Controlling” or
“Controlled” means owned by or possessing the right to grant a license or sublicense without violating the terms of any written agreement between any Third Party and the applicable Party, or without requiring any payment to any
Third Party. [***]. 
 1.15.     “CVS” is defined in the Preamble. 

1.16.     “CVS Services” is defined in is defined in Section 4.1. 

1.17.     “CVS User(s)” means CVS, its Affiliates, its or its Affiliates respective employees (using the
Product (including any Embedded Software therein) solely on behalf and for the benefit of CVS or such Affiliates in the performance of the Permitted Use) or any Authorized Third Party User. 

1.18.     “Dispute” is defined in Section 11.2. 

1.19.     “Dispute Proposal” is defined in Section 11.4 

1.20.     “Dollars” or “$” means lawful money of the United States in immediately available
funds. 
 1.21.     “Effective Date” is defined in the fourth Recital to this Agreement. 

  
 2 

 1.22.     “Embedded Software” means the executable
object code version of LumiraDx’s (or its Affiliates’) proprietary software as embedded in Instruments or other Products. 

1.23.     “Exclusive Field” means retail medical clinics (i.e. clinics located in retail stores) and
retail pharmacy businesses (including retail clinics and pharmacies that operate in conjunction with each other). 

1.24.     “Exclusivity Period” means the period commencing on the Effective Date and, subject to the
following sentence, continuing until one (1) year following the Availability Date. [***]. “Availability Date” means date on which LumiraDx gives written notice to CVS that (a) LumiraDx has produced (or had produced for it)
Product that (i) includes at least one (1) of the eleven (11) Planned Diagnostic Tests listed in “Group 1” in Schedule A hereto and (ii) lawfully may be used to perform such Planned Diagnostic Test(s) in the
Exclusive Field within the Territory (including the receipt of sufficient Regulatory Approvals applicable to such use), and (b) LumiraDx is prepared to provide such Product to CVS in commercially reasonable quantities within a commercially
reasonable period following receipt of orders for such Product under the Supply Agreement (if and when the Supply Agreement is entered into if it has not been entered into at the time such notice is given). 

1.25.     “Facility” means any manufacturing facility of LumiraDx or its Affiliates or one or more of
their respective designees that is certified under Applicable Law for the manufacture of Product and selected by LumiraDx or its Affiliates from time to time. LumiraDx will give CVS written notice of any further change in manufacturing facility as
soon as reasonably practicable after LumiraDx’s decision to move the manufacture of the Product. 
 1.26.
    “FDA” means the United States Food and Drug Administration or any successor agency. 
 1.27.
    “Field” means the Exclusive Field and the Non-Exclusive Field. 
 1.28.
    “Force Majeure Event” is defined in Section 12.3. 
 1.29.
    “Instrument” means the medical diagnostics electronic device being developed (or to be developed, as the case may be) by or on behalf of LumiraDx or its Affiliates or licensees for use with Test Strips to
perform the Planned Diagnostic Tests and any other assays for which LumiraDx or its Affiliates or licensees make Test Strips available. 

1.30.     “Intellectual Property” means, collectively, means any and all rights in any jurisdiction
throughout the world in and to any: (a) Patent Rights; (b) works of authorship, whether copyrightable or not, including mask work rights, utility models, software, databases and compilations, other industrial or intangible property rights
of a similar nature, and all registered and unregistered copyrights; (c) inventions, discoveries, and methodologies, algorithms, formulae, know-how, and trade secrets, in each case, whether or not patented; (d) trademarks, service marks,
logos, trade names, and other indicia of origin; (e) domain names, URLs, rights of personality or publicity, moral rights, and other proprietary or similar rights, including when framed under common law or theories of unfair competition or
tortious interference, so long as designed to protect the intellectual work product; and (f) any and all copies, improvements, modifications, and derivative works thereof. 

1.31.     “Losses” is defined in Section 9.1. 

1.32.     “LumiraDx” is defined in the Preamble. 

1.33.     “LumiraDx Intellectual Property” means the LumiraDx Marks, the LumiraDx Patents and any other
Intellectual Property Controlled by LumiraDx or its Affiliates in the Territory that is reasonably necessary for the use of Product by CVS Users for the Permitted Purpose in accordance with this Agreement. 

  
 3 

 1.34.     “LumiraDx Marks” means those trade name,
trademarks and service marks of LumiraDx or Controlled by LumiraDx or its Affiliates as set forth in Exhibit B hereto, as may be amended by LumiraDx from time to time. 

1.35.     “Lumira Parent” is defined in the second Recital to this Agreement. 

1.36.     “LumiraDx Patents” means the Patent Rights Controlled by LumiraDx or its Affiliates during the
Term that are reasonably necessary for the use of Product by CVS Users permitted by this Agreement. 
 1.37.
    “New York Courts” is defined in Section 12.1(b). 
 1.38.
    “Non-Exclusive Field” means home services for infusion and home dialysis. 
 1.39.
    “Party” is defined in the Preamble. 
 1.40.     “Patent
Rights” means patents, patent applications, statutory invention registrations, and divisions, continuations, continuations-in-part, and substitute applications of the foregoing and any extensions, reissues, restorations, and reexaminations
of the foregoing. 
 1.41.     “Permitted Use” is defined in Section 4.1. 

1.42.     “Person” means any natural person, corporation, firm, limited liability company, limited
liability partnership, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. 

1.43.     “Planned Diagnostic Tests” means the tests listed in Schedule A hereto. 

1.44.     “Preferred Share Subscription Letter” is defined in the second Recital to this Agreement. 

1.45.     “Product(s)” means the Instrument(s) or Consumable(s), as applicable and as context requires.

 1.46.     “Product Development” means the completion of specification, engineering and testing of
Products, as well as activities conducted to obtain Regulatory Approval for Products (including clinical trials). 
 1.47.
    “Recovery” is defined in Section 6.4(e). 
 1.48.     “Regulatory
Approval” means, with respect to a Product in the Territory, all unrestricted approvals, clearances, registrations and permits required under Applicable Law to market such Product in the Territory. 

1.49.     “Regulatory Approval Application” means an application for Regulatory Approval required before
commercial sale or use of a Product as a medical device in any jurisdiction in the Territory. 
 1.50.
    “Representatives” is defined in Section 5.1. 
 1.51.     “Series A
Shares” means the Series A Convertible Preferred Shares of Lumira Parent. 
 1.52.
    “Specifications” means, with respect to a given Product, the written specifications for such Product as set forth in the Regulatory Approval for such Product, as may be amended or updated from time to time
and adopted by LumiraDx. 

  
 4 

 1.53.     “Supply Agreement” is defined in
Section 3.1. 
 1.54.     “Support Agreement” is defined in Section 3.2. 

1.55.     “Term” is defined in Section 8.1. 

1.56.     “Territory” means the fifty states and District of Columbia comprising the country of the
United States of America and its territories and possessions, including the Commonwealth of Puerto Rico. 
 1.57.
    “Test Strips” means, with respect to a given Instrument, the testing strips for use with such Instrument to perform the Planned Diagnostic Tests (and any other assays for which LumiraDx makes such testing
strips available). 
 1.58.     “Third Party(ies)” means any Person other than LumiraDx, CVS, or any
Affiliates of LumiraDx or CVS. 
 1.59.     “Third Party Claims” is defined in Section 9.1. 

 

	2.	 PRODUCT DEVELOPMENT AND REGULATORY APPROVALS. 

2.1.     Product Development. 

(a)     LumiraDx, on its own or through its Affiliates or subcontractors, shall use Commercially Reasonable Efforts to
(i) develop Products to implement the Planned Diagnostic Tests in Territory for use in the Exclusive Field; (ii) obtain and maintain any Regulatory Approvals necessary for commercialization of such Products including such Planned
Diagnostic Tests in the Territory for use in the Exclusive Field and (iii) following receipt of Regulatory Approval for a given Product implementing a Planned Diagnostic Test for use in the Exclusive Field, make such Product commercially
available in Territory for use in the Exclusive Field. In addition, LumiraDx, on its own or through its Affiliates or subcontractors, shall use Commercially Reasonable Efforts to make all of the Planned Diagnostic Tests listed in Schedule A
hereto commercially available in Products in the Territory for use in the Exclusive Field, and without limiting the foregoing, shall increase its priorities relating to the development of Planned Diagnostic Tests relative to LumiraDx’s business
plan. 
 (b)     LumiraDx, on its own or through its Affiliates or subcontractors, will use Commercially Reasonable
Efforts to develop, and obtain Regulatory Approval (on CLIA Waived basis) necessary for commercialization in the Exclusive Field for, Product(s) implementing at least 10 of the Planned Diagnostic Tests [***] in the Territory within the first 24
months following the Effective Date. 
 (c)     All studies, analyses and any other data generated from Product
Development, and all rights therein, including any patent, copyright, trade secret or any other Intellectual Property associated with therewith, will be owned exclusively by LumiraDx. LumiraDx will own all Intellectual Property, regulatory filings
(including Regulatory Approval Applications), documentation (including Documentation) and approvals (including Regulatory Approvals) relating to the Products. 

2.2.     Exclusivity. During the Exclusivity Period, neither LumiraDx nor any of its Affiliates shall, directly or
indirectly (a) authorize anyone other than CVS to use the Products (or any components thereof, including the Embedded Software) in the Exclusive Field in the Territory or (b) knowingly facilitate unauthorized use of the Products (or any
components thereof, including the Embedded Software) in the Exclusive Field in the Territory. For clarity, the foregoing shall not obligate LumiraDx or any of its Affiliates to enforce its or their Intellectual Property against unauthorized users.

  
 5 

 2.3.     Regulatory Approvals. 

(a)     Upon request, LumiraDx will inform CVS of the status of its efforts to obtain Regulatory Approvals for Products in
the Territory. LumiraDx will be responsible for, and as between the Parties (absent LumiraDx’s prior written consent) shall have the sole right to conduct, all communications with any governmental authority or agency concerning the Product.
LumiraDx will inform CVS of any material action taken in connection therewith. All Regulatory Approvals for the Product will be issued under LumiraDx’s name and LumiraDx will own such Regulatory Approvals and all relevant documents associated
with such Regulatory Approvals and corresponding Regulatory Approval Application materials. LumiraDx will bear the costs of obtaining and maintaining all such Regulatory Approvals. 

(b)     Where required by Applicable Law, LumiraDx and CVS will establish by written agreement specific written processes
and procedures for cooperation regarding post-market surveillance and other regulatory requirements. 
 2.4.    
Specifications. LumiraDx will provide written notice to CVS of the Specifications for Product no later than the time that LumiraDx gives notice to CVS that LumiraDx is prepared to begin supplying such Product under the Supply Agreement.
Changes to the Specifications will be addressed in the Supply Agreement. 
 2.5.     Steering Committee. LumiraDx
and CVS will each designate a representative to serve on a steering committee to meet by phone or in person, as the member may elect, so that LumiraDx can update CVS regarding progress on Product Development in order that CVS can plan for use of the
Product and the Parties can timely put in place the Supply Agreement, the Quality Agreement and the Support Agreements. 
  

	3.	 COMMERCIAL AGREEMENTS. 

3.1.     Supply Agreement. The Parties shall negotiate in good faith with a view to entering into, prior to the time
at which LumiraDx is prepared to commence the initial commercial supply of Products to CVS for use in the Field, a supply agreement (the “Supply Agreement”) pursuant to which (x) LumiraDx shall manufacture and supply to CVS
Product for use in the Field during the Term and (y) CVS shall commit to use Commercially Reasonable Efforts to deploy the Product in the Field during the Term. In furtherance of the foregoing (and without limiting the general obligation to
negotiate in good faith), the Parties agree to the following procedures: 
 (a)     Within [***] after
receipt of written request from LumiraDx, CVS shall submit to LumiraDx suggested templates for use as the basis of the agreements contemplated by this Section 3. Such templates shall be based on forms of agreements customarily used by CVS in
similar circumstances and may, if CVS so elects, be appropriately modified in the light of their intended use as the basis for the agreement contemplated by this Section 3. CVS agrees to respond reasonably promptly to questions by LumiraDx
relating to such templates. Notwithstanding the foregoing, LumiraDx acknowledges and agrees that CVS may not have a suitable Quality Agreement template, and therefore if CVS is unable to identify a suitable Quality Agreement template, its
obligations under this Section 3.1(a) shall not apply to the Quality Agreement. 
 (b)     After
LumiraDx gives written notice to CVS that LumiraDx expects to be able to commence commercial supply of commercially reasonable quantities of Products to CVS for use in the Field by a specified date not more than [***] after the date of such notice,
CVS shall, within [***] after receipt of written request from LumiraDx, deliver to LumiraDx a proposal for each of the agreements contemplated by this Section 3 that has not earlier been executed. Each such proposal shall reflect terms that CVS
would be willing to agree to and be in a form which, if accepted by LumiraDx, will constitute a binding agreement with CVS. 

  
 6 

 (c)     If LumiraDx and CVS have failed to agree on any
of the agreements contemplated by this Section 3 within [***] after the date by which CVS is required to propose such agreement, then, at either Party’s written request, the parties will cause their respective personnel with authority to
agree on the terms of such agreements to meet in person for [***] to attempt to negotiate the outstanding terms of such agreements. Such in-person meeting will occur within [***] after the date of such written request and will be conducted in good
faith. Additional in-person meetings may be scheduled by the Parties by mutual agreement, but neither Party shall be obligated to participate in any additional in-person meetings. . 

3.2.     LumiraDx Support. The Parties shall negotiate and enter into, prior to the initial commercial supply of
Products under this Agreement, one or more support and maintenance agreements (“Support Agreement(s)”) pursuant to which LumiraDx shall provide to CVS, throughout the Term, training, diagnostic and other related support and
maintenance services with respect to the Products, including procedures to address compliance with Applicable Laws related to the security and handling of personally identifiable and health information (e.g., HIPAA). 

3.3.     Quality Agreement. In connection with entering into the Supply Agreement the Parties shall enter into a
quality agreement that shall address and govern issues related to the quality of Product supplied for use under this Agreement (“Quality Agreement”). The Quality Agreement shall, among other things: (i) describe each
Party’s responsibilities with respect to quality matters; (ii) include criteria for release and related certificates and documentation; (iii) include criteria and testing procedures for acceptance of Product; (iv) detail
classification of any non-conformance; (v) include details for testing procedures with which the resolution of disputes regarding any Products found to have a non-conformance will be conducted; and (vi) include procedures with respect to
the recall of Product or return of non-conforming Product (including for compliance with LumiraDx’s return materials authorization process), in each case, subject to the terms of Agreement. In the event of any conflict or inconsistency between
this Agreement and the Quality Agreement, the Quality Agreement shall control with respect to the implementation of quality matters, and in all other circumstances this Agreement shall control. For clarity, where an issue is addressed in either this
Agreement or the Quality Agreement and not addressed in the other, there is no conflict or inconsistency. 
 3.4.    
Minimum Purchase Commitments. If the Exclusivity Period is extended beyond the initial period specified in Section 1.24, LumiraDx may require that this Agreement be amended to include [***]. If the parties fail to agree upon such terms
prior such date, then at any time thereafter, either party may require that such terms be finally determined by Special Arbitration pursuant to Section 11.4. 
  

	4.	 INTELLECTUAL PROPERTY LICENSE GRANTS. 

4.1.     License. In the Supply Agreement, LumiraDx will grant (or cause one or more of its Affiliates to grant) to
CVS, subject to the terms and conditions thereof, for the Term, a non-transferable (except as set forth in Section 12.6) license under the LumiraDx Intellectual Property solely as integrated into the Product, solely to the extent necessary for
the following use (the “Permitted Use”): to purchase and permit CVS Users to use Products in the Field in the Territory to sell and provide commercial testing services to CVS’s customers using Product, and for no other purpose
(such services, the “CVS Services”). [***]. All of CVS’s rights herein to purchase and sell Products shall be subject to receipt of any necessary Regulatory Approvals in the Territory. Additional rights and obligations of the
Parties with respect to Products may be set forth in the Supply Agreement and/or the Support Agreement(s). Insofar as LumiraDx has non-exclusive rights to Intellectual Property used in the Product, CVS’s rights with respect to such Intellectual
Property shall be similarly non-exclusive, even in the Exclusive Field (but CVS shall be the exclusive licensee of LumiraDx and its Affiliates in the Exclusive Field during the Term) and if LumiraDx or any of its Affiliates provide any Third-Party
software (and corresponding Third Party Documentation) with a Product, the terms of any agreement (including pre-packaged terms and conditions, such as an end-user license) pertaining to such Third-Party software (and Third Party Documentation) will
prevail over this Agreement, and the licenses granted in the Supply Agreement shall not apply to any such Third-Party software (and Third Party Documentation). 

  
 7 

 4.2.     Limitations on Use. In the Supply Agreement, CVS will
agree that it will not, and it will not authorize any other Person, directly or indirectly, to engage in any of the following activities: (i) use, distribute, ship, perform, sell, re-sell, transfer or otherwise provide any Product for any use
other than the Permitted Use, (ii), use, distribute, ship, perform, sell, re-sell, transfer or otherwise provide any Product for any use with a product, software or service other than another Product, (iii) use, distribute, ship, perform, sell,
re-sell, transfer or otherwise provide any Product or outside of the Field, (iv) disassemble, reverse-engineer, reverse-compile or reverse-assemble any Product, (v) separate, extract or isolate components of any Product to any analysis not
authorized in the Specifications, (vi) in any manner decode the object code of any Embedded Software in order to derive, obtain or perceive the source code from which any component thereof is compiled or interpreted, (vii) grant a
sublicense to any rights received hereunder or (viii) permit any customers or other Person to perform any of the acts listed in this Section 4.2. CVS will include such contractual restrictions on (i) all contracts with Affiliates or
Third Parties relating to any Product, and (ii) all labeling and other documentation relating to any Product or the CVS Services. 

4.3.     Unauthorized Uses. In the Supply Agreement, CVS will agree that (a) the activities prohibited by
Section 4.2 (i) are, without limitation, part of the bargained for conditions of sale of the Products, (ii) are not included within the rights to be expressly provided to CVS pursuant to Section 4.1, and (iii) each,
including restrictions against the use of the Product to perform any of those activities, is an unauthorized use, may infringe LumiraDx Intellectual Property, and is part of the bargained for conditions of sale of the Products; and (b) any
violation of or breach of any provision of Section 4.2 or this Section 4.3 or any use of the Products outside the scope of the rights expressly granted to CVS pursuant to Section 4.1 is a material breach of this Agreement. In
connection with any transaction or agreement relating to any Product with a Third Party, CVS will restrict (through contracts, labeling and/or other documentation) such Third Party from conducting any of the activities listed in Section 4.2,
Section 4.2 or this Section 4.3. CVS will exercise all of its rights to enforce all such restrictions at law and in equity against such Third Party, including by notifying LumiraDx promptly in writing of such alleged violation discovered
by CVS (and in any event within thirty (30) days of such discovery). In addition, any warranty (including Product Warranty) granted by LumiraDx with respect to Product shall be deemed void if any Product covered by such warranty is used for any
purpose other than the Permitted Use or otherwise in violation of this Agreement, including, any use restrictions referred to in Section 4.2, Section 4.2 or this Section 4.3. 

4.4.     Reservation of Rights. 

(a)     Except as expressly set forth herein, LumiraDx reserves all right, title and interest in the LumiraDx Intellectual
Property, and CVS will not acquire, or be deemed to have acquired, any right, title or interest whatsoever as a result of this Agreement in the LumiraDx Intellectual Property or the Intellectual Property of any of its Affiliates. 

(b)     Except as expressly set forth herein, CVS reserves all right, title and interest in all Intellectual Property of
CVS and its Affiliates, and LumiraDx will not acquire, or be deemed to have acquired, any right, title or interest whatsoever as a result of this Agreement in such Intellectual Property. 

 

	5.	 CONFIDENTIALITY. 

5.1.     Confidentiality; Exceptions. The Parties acknowledge that discussions between and among LumiraDx, CVS and
their respective Affiliates will necessarily require the exchange of information (including detailed financial and Product information) that is considered confidential and proprietary by the disclosing Party and its Affiliates. The Parties agree for
themselves and their Affiliates that any confidential or proprietary information relating to the business of the disclosing Party which such Party discloses to the other Party pursuant to this Agreement will be considered “Confidential
Information” and will include, without limitation, all of the 

  
 8 

 
following of the disclosing Party and its Affiliates: (i) earnings, costs, and other financial information; (ii) drawings, formulations, samples, technical data, photographs,
manufacturing methods, testing procedures; (iv) marketing, sales and customer information; (v) all clinical studies; and (v) all other information related to the Product. For the avoidance of doubt, the Specifications, data and
results from clinical studies relating to the Product, and Product Development] and any other information related to the Product will be deemed to be LumiraDx’s Confidential Information. In addition, the terms and conditions of this Agreement
will be deemed both Parties’ Confidential Information. Except to the extent authorized by this Agreement or otherwise agreed in writing, the Parties agree that from the Effective Date, subject to and except as permitted by Section 5.2,
each Party will keep confidential (and will cause the Affiliates and its and their respective directors, managers, officers, employees, agents, consultants, advisors and sublicenses (collectively referred to herein as
“Representatives”) to keep confidential) and will not publish or otherwise disclose or use for any purpose, other than as provided for in this Agreement, the Confidential Information of the other Party, except to the extent the
receiving Party’s Representatives need to know such Confidential Information in order to discharge such Party’s obligations and exercise its rights hereunder and are subject to written obligations of confidentiality no less protective of
such Confidential Information than this Section 5. Each Party and its Affiliates may also use or disclose any Confidential Information obtained from the other Party and its Affiliates: (i) in connection with bringing or defending any
litigation or other dispute resolution proceeding with respect to disputes under this Agreement, (ii) to agents, advisors, investors and potential investors and acquirers under confidentiality provisions at least as stringent as those in this
Agreement; and (iii) to the extent requested or required (by oral questions, interrogatories, requests for information or documents, subpoena, civil, criminal, legislative or similar process or, in the opinion of counsel for such party, by
federal or state securities or other Applicable Law or the rules, requirements or guidance of any securities exchange or self-regulatory organization) to be disclosed, provided that the Party requested or required to make such disclosure (to the
extent legally permitted) will give the other Party reasonable advance written notice of such disclosure requirements, to the extent possible, and will cooperate with such Party and use reasonable efforts to secure confidential treatment of such
Confidential Information or waive the requirements of this Section 5.1, including but not limited to obtaining an order protecting the information from public disclosure. For the avoidance of doubt: in the event any Party uses the other
Party’s Confidential Information for any purpose other than as provided for in this Agreement such use will constitute a breach of this Agreement, as the case may be. Each Party will protect the other Party’s Confidential Information from
unauthorized use, access or disclosure in the same manner that it protects its own similar Confidential Information (but using, at minimum, a commercially reasonable degree of care). Confidential Information will not include information which: 

(a)     was in the lawful knowledge and possession of the receiving Party or its Representatives, free of a duty of
confidentiality, prior to the time it was disclosed to, or learned by, the receiving Party hereunder, or 
 (b)     was
developed independently by the receiving Party or its Representatives without use of or access to the Confidential Information of the disclosing Party; 

(c)     was available to the public or otherwise part of the public domain at the time of its disclosure to the receiving
Party; 
 (d)     became available to the public or otherwise part of the public domain after its disclosure other than
through any act or omission of the receiving Party or its Representatives in breach of this Agreement or other written agreement between the Parties; or 

(e)     was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had
no obligation to the disclosing Party not to disclose such information to others. 

  
 9 

 Each Party will be responsible and liable for all breaches of the confidentiality provisions of this
Agreement by its Representatives. This Section shall survive for a period of three (3) years after the expiration or termination of this Agreement. 

5.2.     Publications. Notwithstanding any other provision of this Agreement, including, but not limited to the
provisions of Section 5.2, LumiraDx may publish the results of any Product Development activities and the results of the post-marketing clinical trials relating to the Product. 

5.3.     Public Announcements. 

(a)     Neither Party will issue any other press release or other publicity materials, or make any public presentation with
respect to the existence of, or any of the terms or conditions of, this Agreement or the programs or efforts being conducted by the other Party hereunder, in each case without the prior written consent of the other Party (such consent not to be
unreasonably withheld, conditioned or delayed) save only such announcements that are required by or advisable (upon the advice of such Party’s legal counsel) to be made under Applicable Law or the rules of any securities exchange, in which case
the other Party will at least be provided with a copy of such announcement prior to its release. Notwithstanding the foregoing prior written consent requirement, each Party is hereby granted the right to issue a press release with respect to this
Agreement without the prior written consent of the other Party in connection with statements in quarterly or annual press releases reporting the Party’s quarterly or yearly financial or operating results to the extent they relate to such
financial or operating results, and (iii) a press release upon the happening of the following events: execution of this Agreement, the filing of any Regulatory Approval Applications, the receipt of any Regulatory Approvals, any significant
clinical trial development (including initiation and/or completion of a clinical trial) and commercialization in any country or region, provided that in the case of clause (iii) the content of such release is reasonably satisfactory to the
other Party. Notwithstanding the foregoing, if either Party issues any publicity, press release or other announcement in accordance with this Section 5.2, the other Party will thereafter have the right to disclose publicly the information in
such publicity, press release or other announcement without the prior written approval of the other Party. 
 (b)     In
the event of such publication, press release or public announcement described in Section 5.3(a) for which the prior written consent of the other Party is required or the content of which must be reasonably satisfactory to the other Party, the
Party making the announcement will give the other Party at least reasonable advance written notice of the text of the announcement so that the other Party will have an opportunity to comment upon the announcement. Notwithstanding the foregoing,
however, where urgent, unusual and rare circumstances require immediate disclosure upon the advice of the Party’s legal counsel, a Party will, unless impossible or inadvisable because of legal reasons, provide at least one (1) Business
Day’s advance written notice of such disclosure to the other Party. Notwithstanding anything contained in this Agreement to the contrary, each Party acknowledges that the other Party is permitted to file this Agreement with the Securities and
Exchange Commission and to disclose the terms of this Agreement in such Party’s reports or registration statements filed with or furnished to the Securities and Exchange Commission, provided that such Party will use its Commercially Reasonable
Efforts to obtain confidential treatment with respect to the commercially sensitive terms contained herein; provided, further, that such Party’s ongoing financial reporting of the transactions contemplated by this Agreement in its reports or
registration statements filed with or furnished to the Securities and Exchange Commission will be consistent with such Party’s past financial reporting practices as may be modified from time to time by the requirements of Applicable Law,
regulation or accounting principles generally accepted in the United States. 
  

	6.	 INTELLECTUAL PROPERTY.  

6.1.     Title. 

(a)     Each Party will retain sole and exclusive ownership of its respective Intellectual Property (i) developed,
conceived, obtained, licensed, or acquired by either Party prior to the Effective Date of this 

  
 10 

 
Agreement; or (ii) developed, conceived, obtained, licensed, or acquired by either Party independently of this Agreement and without use of or access to the other Party’s Intellectual
Property. Except as expressly set forth in this Agreement, neither Party grants to the other Party under this Agreement any license or right whether by implication, estoppel or otherwise, under Intellectual Property now or hereafter Controlled by
the Party. 
 (b)     [***]. 

6.2.     Cooperation. The Parties will in good faith assist one another and cooperate in the filing, prosecution,
maintenance, litigation, settlement discussion or negotiation with respect to any of the Patent Rights described in Section 6.1 at LumiraDx’s reasonable request and expense, unless otherwise provided in this Section 6. 

6.3.     Patent Filings. 

(a)     LumiraDx will have the sole right and discretion whether to prosecute and maintain the patent protection for
technology and inventions deployed in Product and whether to defend the LumiraDx Patents against any actions and/or proceedings initiated at a patent office (e.g., reexaminations, oppositions and nullity actions). 

(b)     Costs incurred during the Term for the preparation, filing, prosecution and maintenance expenses, in each case
incurred in connection with the establishment and maintenance of the LumiraDx Patents will be the sole responsibility of LumiraDx. LumiraDx retains the right to prepare, file, prosecute and maintain any LumiraDx Patent, including any patent and
patent applications relating to an invention developed in any jurisdiction, at LumiraDx’s sole cost and expense. 

6.4.     Enforcement Against Infringers. 

(a)     Notice. If CVS learns that a Third Party is infringing or allegedly infringing any LumiraDx Patent, or if
any Third Party claims that any such patent is invalid or unenforceable, CVS will promptly notify LumiraDx thereof including available evidence of infringement or the claim of invalidity or unenforceability. CVS will cooperate in a commercially
reasonable manner in connection with any efforts undertaken by LumiraDx (at its sole cost and expense) to stop such alleged infringement or to address such claim without litigation. 

(b)     Enforcement and Defense of Patents. LumiraDx will have the right (but not the obligation) to take the
appropriate steps to enforce or defend any LumiraDx Patent at its own cost and expense, in its own name and entirely under its own direction and control. LumiraDx may take steps including the initiation, prosecution and control of any suit,
proceeding or other legal action by counsel of its own choice and CVS will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(c)     If LumiraDx brings any suit, action or proceeding under Section 8.4(b), at LumiraDx’s election, CVS or
the applicable CVS User, except as provided below, will be joined as party plaintiff if necessary to prosecute the suit, action or proceeding and to give LumiraDx reasonable authority to file and prosecute the suit, action or proceeding. Any such
joinder will be at LumiraDx’s expense and neither CVS nor any CVS User will be required to transfer any right, title or interest in or to any property to LumiraDx or any other party to confer standing on a Party hereunder and except as provided
below, LumiraDx shall indemnify CVS against any and all liabilities or losses incurred by CVS or its Affiliate as a result of such joinder. If CVS or the applicable CVS User is prohibited by any contract from joining such an action, it shall not be
indemnified with respect to matters arising from the breach of such contract unless CVS or the applicable CVS User discloses such contract to LumiraDx in writing at the time LumiraDx requests that CVS or the applicable CVS User join such action, and
LumiraDx thereafter confirms its request that CVS or the applicable CVS User join such action. 

  
 11 

 (d)     Cooperation. CVS will provide reasonable assistance to
LumiraDx, including by providing access to relevant documents and other evidence and making its employees available, subject to LumiraDx’s reimbursement of any out-of-pocket expenses incurred by CVS in providing such assistance. 

(e)     Damages. Any settlements, damages or other monetary awards (each a “Recovery”) recovered
pursuant to a suit, action or proceeding brought pursuant to Section 6.4(b) will be the sole property of LumiraDx. 
  

	7.	 REPRESENTATIONS AND WARRANTIES. 

7.1.     Representations and Warranties of LumiraDx. LumiraDx hereby represents and warrants to CVS as follows as of
the Effective Date: 
 (a)     LumiraDx is a corporation duly organized, validly existing and in good standing under the
laws of the state of Delaware and has all requisite corporate power and lawful authority to own, lease and operate its assets and to carry on its business as currently conducted. LumiraDx has the full legal right, corporate power and authority to
execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the performance by LumiraDx of its obligations hereunder do not and will not violate any provision of
Applicable Law or any provision of the certificate of incorporation or bylaws of LumiraDx and do not and will not conflict with or result in any breach of any condition or provision of, or constitute a default under, any contract, mortgage, lien,
lease, agreement, indenture, instrument, judgment or decree to which LumiraDx is a party or by which its properties are bound. 

(b)     This Agreement has been duly executed and delivered by LumiraDx and constitutes the valid and binding obligation
of LumiraDx, enforceable against LumiraDx in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally or by general equitable
principles. No action, approval, consent or authorization, including but not limited to, any action, approval, consent or authorization by any Person, governmental or quasi-governmental agency, commission, board, bureau or instrumentality, is
necessary as to LumiraDx in connection with the execution and delivery of this Agreement and the performance by LumiraDx of its obligations hereunder. 

(c)     Except for rights that have been terminated in writing prior to the Effective Date and no longer have any force or
effect, LumiraDx has not granted to any Third Party a right to use the Product in the Exclusive Field in the Territory during the Exclusivity Period. 

(d)     The use of the Product in the Field and in the Territory are not the subject of any written notice or written
claim received by LumiraDx regarding any infringement of any Third Party rights. 
 (e)     LumiraDx has not filed for
bankruptcy, is not insolvent, has not proposed a compromise or arrangement to its creditors generally, has not had any petition or a receiving order in bankruptcy filed against it, has not made a voluntary assignment in bankruptcy, has not taken any
proceeding with respect to a compromise or arrangement with its creditors, has not taken any proceeding to have it declared either bankrupt or liquidated, has not taken any proceeding to have a receiver appointed for any part of its assets, and has
not had any execution, charging order, levy or distress warrant become enforceable or become levied upon any of its assets. 

7.2.     Representations and Warranties of CVS. CVS hereby represents and warrants to LumiraDx as follows as of the
Effective Date: 
 (a)     CVS is a corporation duly organized, validly existing and in good standing under the laws of
Rhode Island and has all requisite corporate power and lawful authority to own, lease and operate its assets and to carry on its business as currently conducted. CVS has the full legal right, corporate power and authority to

  
 12 

 
execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the performance by CVS of its obligations hereunder do
not and will not violate any provision of Applicable Law or of any provision of the Certificate of Incorporation of CVS and do not and will not conflict with or result in any breach of any condition or provision of, or constitute a default under,
any contract, mortgage, lien, lease, agreement, indenture, instrument, judgment or decree to which CVS is a party or by which its properties are bound. 

(b)     This Agreement has been duly executed and delivered by CVS and, assuming the accuracy of Sections 7.1(a) and
7.1(b), constitutes the valid and binding obligation of CVS, enforceable against CVS in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’
rights generally or by general equitable principles. No action, approval, consent or authorization, including but not limited to, any action, approval, consent or authorization by any Person, governmental or quasi-governmental agency, commission,
board, bureau or instrumentality, is necessary as to CVS in connection with the execution and delivery of this Agreement and the performance by CVS of its obligations hereunder. 

(c)     CVS has not filed for bankruptcy, is not insolvent, has not proposed a compromise or arrangement to its creditors
generally, has not had any petition or a receiving order in bankruptcy filed against it, has not made a voluntary assignment in bankruptcy, has not taken any proceeding with respect to a compromise or arrangement with its creditors, has not taken
any proceeding to have it declared either bankrupt or liquidated, has not taken any proceeding to have a receiver appointed for any part of its assets, and has not had any execution, charging order, levy or distress warrant become enforceable or
become levied upon any of its assets. 
 7.3.     NO IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED HEREIN,
NEITHER PARTY MAKES ANY WARRANTIES, EXPRESSED, IMPLIED, WRITTEN OR ORAL AND ALL OTHER WARRANTIES, EXPRESS, IMPLIED, WRITTEN OR ORAL, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, TITLE, FITNESS FOR A
PARTICULAR PURPOSE AND ANY IMPLIED WARRANTY ARISING OUT OF A COURSE OF DEALING, CUSTOMER USAGE OR TRADE ARE HEREBY DISCLAIMED. THE ONLY REPRESENTATIONS AND WARRANTIES ARE IN THIS SECTION 7. NO OTHER REPRESENTATIONS AND WARRANTIES ARE BEING MADE. CVS
ACKNOWLEDGES THAT IT HAS NOT RELIED ON ANY OTHER REPRESENTATIONS OR WARRANTIES. 
  

	8.	 TERM AND TERMINATION. 

8.1.     Term. The “Term” of this Agreement will commence on the Effective Date and will expire on
the expiration of the Exclusivity Period, subject to the termination and extension provisions set forth herein. 

8.2.     Termination by Either Party for Cause. Notwithstanding any of the foregoing, this Agreement may be
terminated by a Party upon written notice to the other Party upon the occurrence of any of the following: 
 (a)     a
material breach of any term or condition of this Agreement by the other Party which is amenable to cure, and the breaching Party will have failed to cure such breach within ninety (90) days from the receipt by it of written notice thereof from
the other Party; 
 (b)     a material breach of this Agreement or the Supply Agreement by the other Party which is not
amenable to cure or breach or failure of CVS to meet any minimum purchase commitment under the Supply Agreement. 
 (c)
    the other Party will commence any case, proceeding or other action (i) under any Applicable Law relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for

  
 13 

 
relief entered with respect to it, or seeking to adjudicate it as bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, wind-up, liquidation, dissolution, composition or
other relief with respect to it or its debts, provided, however, this subclause will not apply to any Affiliate of such other Party, or (ii) seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or
any substantial part of its assets; 
 (d)     there will be commenced against the other Party any such case, proceeding
or other action referred to in Section 8.2(c) which results in the entry of an order for relief; 
 (e)     the
other Party taking any action authorizing, or in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth above in Section 8.2(c) or Section 8.2(d); 

(f)     the other Party admitting in writing its inability generally to pay its debts as they become due; or 

(g)     if by reason of a Force Majeure Event, as described in Section 12.3, the obligations imposed hereunder or
thereunder cannot be discharged by the other Party for a period of more than [***], provided that if at the end of such [***] period LumiraDx and CVS agree that such Force Majeure Event is not expected to prevent performance for an additional [***],
then this termination right will not be exercisable until the expiration of such additional [***] period and will be of no force or effect with respect to such Force Majeure Event if such other Party resumes performance under this Agreement by the
end of such additional [***] period. 
 8.3.     Termination by CVS Without Cause. Notwithstanding any of the
foregoing, this Agreement may be terminated by a CVS without cause upon written notice to LumiraDx at any time. 

8.4.     Effect of Termination. 

(a)     Upon expiration or termination of this Agreement for any reason, all rights and licenses granted to CVS pursuant to
this Agreement will immediately terminate. 
 (b)     Upon expiration or termination of this Agreement for any reason,
each Party will promptly upon request by the other Party return to the other Party or destroy (at the returning Party’s request) all of the other Party’s Confidential Information in the possession or control of the returning Party or its
sublicensees. 
 8.5.     Accrued Rights; Surviving Obligations. 

(a)     Termination of this Agreement for any reason will be without prejudice to any Party’s obligations which will
have accrued prior to such termination including, without limitation, any claim for which indemnification can be made under Section 9, or to the remedy, in accordance with the terms herein, of either Party in respect of any previous breach of
any covenant contained herein, as applicable. 
 (b)     Such termination will not relieve either Party from obligations
that are indicated to survive termination or expiration of this Agreement. 
 (c)     The rights and obligations of the
respective parties pursuant to Section 1 (Definitions), Section 5 (Confidentiality), Section 6 (Intellectual Property), Section 7.3 (No Implied Warranties), Section 8 (Term and Termination), Section 9 (Indemnification),
Section 10 (Limitation of Liability), Section 11 (Dispute Resolution), Section 12 (Miscellaneous) shall survive the termination or expiration of this Agreement and shall bind the parties and their legal representatives, successors and
permitted assigns. Any other provisions of this Agreement contemplated by their terms to pertain to a period of time following termination or expiration of this Agreement shall survive. 

  
 14 

	9.	 INDEMNIFICATION. 

9.1.     Indemnification by LumiraDx. Subject to Section 9.3, LumiraDx will indemnify CVS, its Affiliates and
their respective directors, officers, employees, licensors and agents, and their respective successors, heirs and assigns, and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses
(including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) to the
extent arising from or occurring as a result of: 
 (a)     breach by LumiraDx (or its Affiliates) of this Agreement or
any Applicable Law; or 
 (b)     gross negligence or willful misconduct of LumiraDx, its Affiliates, or anyone acting
on LumiraDx’s or its Affiliate’s behalf in performance of this Agreement; or 
 (c)     [***]. 

9.2.     Indemnification by CVS. CVS will indemnify LumiraDx, its Affiliates and their respective directors,
officers, employees, licensors and agents, and their respective successors, heirs and assigns, and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims to the extent arising
from or occurring as a result of: 
 (a)     breach by CVS (or its Affiliates) of this Agreement or any Applicable Law;

 (b)     [***]; 

(c)     gross negligence or willful misconduct of CVS, its Affiliates or any CVS Users (or anyone acting on CVS, its
Affiliate’s or CVS User’s behalf). 
 9.3.     Exceptions to LumiraDx’s Obligations.
Notwithstanding anything contained in this Agreement to the contrary, the Parties agree that LumiraDx will have no liability to CVS under this Agreement or otherwise for claims, losses, or liability of any kind based upon or related to breach by CVS
of the Supply Agreement. Additionally, any exceptions to LumiraDx’s liability that are included in the mutually executed Supply Agreement shall apply under this Agreement as well. 

9.4.     Indemnification Procedures. If CVS or LumiraDx intends to claim indemnification under this Section 9
as a result of a Third Party Claim or suit, such Party (the “Claiming Party”) will (a) promptly notify the other Party in writing of any claim or loss for which it intends to claim such indemnification, (b) use its
Commercially Reasonable Efforts to cooperate with the other Party and its legal representatives in the investigation of any claim or loss covered by this Section 9, and (c) allow the other Party to control the defense and/or disposition of
such suit or claim; provided that the Claiming Party will have the right to participate at its own expense through counsel of its own choosing. Neither Party will have any indemnification obligations hereunder to the extent that such Party’s
ability to defend such suit or redress such loss is materially prejudiced by the Claiming Party’s failure to perform the obligations under subclause (b) of the preceding sentence. No claim will be settled for which any indemnifying Party
will be liable without the advance written consent of both the indemnifying Party and the Claiming Party, which consent will not be unreasonably withheld. 

9.5.     Mitigation of Damages. Each Party will (and will cause its Affiliates, and in the case of CVS, other CVS
Users, to) use reasonable commercial efforts to pursue all legal rights and remedies available in order to minimize the losses for which indemnification is provided to it under this Section 9. 

  
 15 

 10.     LIMITATION OF LIABILITY. NEITHER PARTY WILL IN ANY EVENT BE
LIABLE TO THE OTHER FOR LOST PROFITS, PUNITIVE, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER SUCH DAMAGES ARE BASED ON TORT, WARRANTY, CONTRACT OR ANY
OTHER LEGAL THEORY, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, PROVIDED, THAT THIS LIMITATION WILL NOT LIMIT A PARTY’S LIABILITY WITH RESPECT TO (A) A BREACH BY A PARTY OF ITS CONFIDENTIALITY OBLIGATIONS
HEREUNDER, (B) INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS, (C) FRAUD, OR (D) THE INDEMNIFICATION OBLIGATION OF SUCH PARTY UNDER THE PROVISIONS OF SECTION 9. 

 

	11.	 DISPUTE RESOLUTION. 

11.1.     Dispute Resolution. 

(a)     In the case of any claim, dispute or controversy between the Parties arising out of or in connection with or
relating to this Agreement (including, without limitation, disputes with respect to the rights and obligations of the Parties following termination), and in case this Agreement does not provide a solution for how to resolve such disputes, the
Parties shall endeavor to discuss and negotiate in good faith towards a solution acceptable to both Parties and in the spirit of this Agreement. If the Parties fail to reach agreement within [***], then for a further [***] period a senior officer of
LumiraDx and a senior officer of CVS shall discuss in good faith an appropriate resolution to the dispute. 
 (b)
    Prior to commencement of arbitration pursuant to Section 11.2, the Parties must attempt to mediate their dispute using a professional mediator from the CPR Institute for Dispute Resolution. Within a period of [***] after
the request for mediation, the Parties agree to convene with the mediator, with business representatives present, for at least one session to attempt to resolve the matter. In no event will mediation delay commencement of the arbitration for more
than [***] absent agreement of the Parties or interfere with the availability of emergency relief. Any disputes concerning the propriety of the commencement of the arbitration shall be finally settled by arbitration pursuant hereto. 

11.2.     Arbitration. [***]. 

11.3.     Injunctive Relief. Each Party hereby acknowledges that, in the event it violates, or threatens to
violate, any of the covenants herein, the other Party will be entitled to seek from any court of competent jurisdiction, without the posting of any bond or other security, injunctive relief, which rights will be cumulative and in addition to any
other rights or remedies in law or equity to which it may be entitled. 
 11.4.     Special Arbitration. [***].

  

	12.	 MISCELLANEOUS. 

12.1.     Governing Law; Consent to Jurisdiction. Except as provided in Section 11 

(a)     all disputes, claims or controversies arising out of this Agreement, or the negotiation, validity or performance
of this Agreement, or the transactions contemplated hereby will be governed by and construed in accordance with the laws of the State of New York without regard to its rules of conflict of laws; and 

(b)     each of the Parties hereto hereby irrevocably and unconditionally consents to submit to the sole and exclusive
jurisdiction of the courts of the State of New York and of the United States of America located in the State of New York (the “New York Courts”) for any litigation among the Parties hereto arising out of or

  
 16 

 
relating to this Agreement, or the negotiation, validity or performance of this Agreement, waives any objection to the laying of venue of any such litigation in the New York Courts and agrees not
to plead or claim in any New York Court that such litigation brought therein has been brought in any inconvenient forum or that there are indispensable Parties to such litigation that are not subject to the jurisdiction of the New York Courts. 

12.2.     Complete Agreement. This Agreement, including the exhibits hereto, which are hereby incorporated into
this Agreement by this reference, constitutes the entire agreement between the Parties with respect to the subject matter hereof. It supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such
subject matter, and prevails over any conflicting terms or conditions contained on printed forms submitted with purchase orders, sales acknowledgments or quotations. This Agreement may not be modified or waived, in whole or part, except in writing
and signed by an officer or duly authorized representative of both Parties. 
 12.3.     Force Majeure. No Party
hereto will have any liability under this Agreement for such Party’s failure or delay in performing any of the obligations imposed by this Agreement to the extent such failure or delay is the result of any of the following events (each, a
“Force Majeure Event”): (i) any fire, explosion, unusually severe weather, natural disaster or Act of God; (ii) epidemic; any nuclear, biological, chemical, or similar attack; any other public health or safety emergency;
any act of terrorism; and any action reasonably taken in response to any of the foregoing; (iii) any act of declared or undeclared war or of a public enemy, or any riot or insurrection; (iv) damage to machinery or equipment; any disruption
in transportation, communications, electric power or other utilities, or other vital infrastructure; or any means of disrupting or damaging internet or other computer networks or facilities; (v) any strike, lockout or other labor dispute or
action; (vi) any action taken in response to any of the foregoing events by any civil or military authority; or (vii) any other event reasonably beyond such Party’s control; provided that financial inability in and of itself will not
be a Force Majeure Event. 
 12.4.     Severability. The terms and conditions of this Agreement are severable. If
any term or condition of this Agreement is deemed to be illegal or unenforceable under any rule of law, all other terms will remain in force. Further, the term or condition which is held to be illegal or unenforceable will remain in effect as far as
possible in accordance with the intention of the Parties as of the Effective Date. 
 12.5.     Relationship of the
Parties. Nothing in this Agreement will be construed to place the Parties hereto in an agency, employment, franchise, joint venture, or partnership relationship. Neither Party will have the authority to obligate or bind the other in any manner,
and nothing herein contained will give rise or is intended to give rise to any rights of any kind to any Third Parties. Neither Party will represent to the contrary, either expressly, implicitly or otherwise. 

12.6.     Assignment; Binding Effect. Neither Party may assign or transfer this Agreement in whole or in part, by
operation of law or otherwise, without the prior written consent of the other Party, except that either Party (the “Assigning Party”) may assign or transfer this Agreement without the written consent of other Party to (a) an
entity that is an Affiliate before and after such assignment or transfer or (b) a corporation or other business entity succeeding to all or substantially all the assets and business of the Assigning Party to which this Agreement relates by
merger or purchase, provided that such corporation or other business entity expressly assumes all of the terms and conditions of this Agreement. No such assignment shall relieve the assigning party from its obligations under this Agreement. Any
attempted assignment, delegation or transfer by an Assigning Party in violation hereof will be null and void. Subject to the foregoing, this Agreement will be binding on the Parties and their successors and assigns. 

12.7.     Notices. All notices hereunder will be in writing and will be deemed given if delivered personally or by
email transmission, or if mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following address (or at such other address for a Party as will be specified by
like notice; provided, that notices of a change of address will be effective only upon receipt thereof). 

  
 17 

 If to LumiraDx, addressed to: 

LumiraDx, Inc. 
 221 Crescent St,
Waltham, MA 02453 
 Attention: Chief Executive Officer 

email: [***] 
 With a copy to (which will not
constitute notice to LumiraDx): 
 LumiraDx, Inc. 

221 Crescent St, Waltham, MA 02453 

Attention: General Counsel 

email: [***] 
 If to CVS, addressed to: 

CVS Pharmacy, Inc. 
 695 George
Washington Highway 
 Mail Code 2 

Lincoln, Rhode Island 02865 

Attention: [***] 
 email: [***]

 With a copy to (which will not constitute notice to CVS): 

CVS Pharmacy, Inc. 
 One CVS
Drive 
 Mail Code 1000 

Woonsocket, Rhode Island 02895 

Attention: [***] 
 email: [***]

 12.8.     No Waiver. Failure by either Party to enforce any provision of this Agreement will not be deemed a
waiver of future enforcement of that or any other provision. 
 12.9.     Interpretation. This Agreement has been
prepared jointly and will not be strictly construed against either Party. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references
herein to Sections and Exhibits shall be deemed references to Sections of and Exhibits to, this Agreement unless the context shall otherwise require. “Herein,” “hereby,” “hereunder,” “hereof” and other
equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. The term “or” means “and/or” hereunder. All definitions set forth herein will be
deemed applicable whether the words defined are used herein in the singular or the plural. References to any specific law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement law
thereto. 
 12.10.     Counterparts and Electronic Copies. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, and such counterparts will together constitute one and the same instrument. For purposes hereof, an electronic copy (including a portable data format (PDF) copy) of this Agreement, including
the signature pages hereto, will be deemed to be an original. 

  
 18 

 12.11.     Headings. The headings and captions used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 [THE REMAINDER OF THIS
PAGE INTENTIONALLY LEFT BLANK] 

  
 19 

 IN WITNESS WHEREOF, the undersigned have duly executed and delivered this Agreement as a
sealed instrument effective as of the date first above written. 
  

													
	CVS Pharmacy, Inc.	 		 	LumiraDx, Inc.
					
	By:	 	 /s/ Mario Ramos
	 		 	By:	 	 /s/ Dorian LeBlanc

		 	Name:	 	Mario Ramos	 		 		 	Name:	 	Dorian LeBlanc
		 	Title:	 	Senior Vice President	 		 		 	Title:	 	CFO

 Schedule A 

[***] 

  
 22EX-10.10

 Exhibit 10.10 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if
publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Purchase Agreement Between CVS Pharmacy, Inc. 

And 
 LumiraDx, Inc

  

	1.	 Overview and Background of Agreement 

This Purchase Agreement (this “Agreement”) is effective 14 August 2020 (“Effective Date”) by and between LumiraDx
Inc, a Delaware corporation, with offices located at 221 Crescent Street, Waltham, MA 02453 (“Vendor or LumiraDx”) and CVS Pharmacy, Inc., a Rhode Island corporation, on its own behalf and on behalf of its subsidiaries and
affiliates, including without limitation MinuteClinic, L.L.C. on behalf of itself, its subsidiaries and its managed entities, with offices located at One CVS Drive, Woonsocket, RI 02895 (hereinafter individually and collectively called
“CVS”). 
 Vendor is the developer of the LumiraDx Platform, a portable point of care test system (the “LumiraDx
Instrument”). Vendor is in the process of developing a COVID-19 antigen assay test strip as well as a COVID-19 antibody assay test strip (collectively, the
“COVID-19 Test Strips”) which can run on Vendor’s LumiraDx Instrument. 

Vendor is seeking Emergency Use Authorization from the Food and Drug Administration (“EUA FDA Approval”) for the LumiraDx
Instrument and COVID-19 Test Strips. Vendor acknowledges that additional FDA approvals may need to be obtained in the future, in addition to the EUA FDA Approval(s) (collectively the “FDA
Approvals”). 
 The obligations set forth in this Agreement are subject to Vendor obtaining and maintaining the appropriate FDA
Approvals now and in the future for the LumiraDx Instrument and COVID-19 Test Strips as well as the ancillary equipment, including collection supplies (“Ancillary Equipment”) necessary to
administer the tests (collectively the “Products”) that expressly authorizes use of the LumiraDx Instrument and COVID-19 Tests strips in patient care settings outside of the clinical
laboratory environment. If Vendor fails to obtain and/or maintain FDA Approvals required for Vendor to make the Products available to CVS and for CVS to be able to use, sell and distribute the Products in compliance with all applicable laws
(including but not limited to laws, statutes, codes, ordinances, rules, regulations, declarations, decrees, directives, recognized international and local industry quality standards, legislative enactments and court (or other governmental,
administrative or regulatory) orders, including the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. § 321 et seq.) and health authority requirements) (“Applicable Laws”) in effect as of July 31, 2020, Vendor will be
entitled to terminate this Agreement as set forth in Section 5.2. 

	2.	 Product Provided 

 

	 	2.1	 Geographic Scope and Shipping 

Vendor agrees to make the Products available in the United States, including its territories, provinces and possessions (collectively the
“United States”), to CVS for purchase to the designated CVS regional distribution centers or through an approved distributor designated by CVS, such designated distributor may be changed in CVS’s sole discretion provided the
total costs related to utilization of such new distributor shall not increase more than [***], in which case Vendor approval shall be required, which shall not be unreasonably withheld. Costs related to utilization of a distributor will be shared
equally between the Parties subject to the following allocation: CVS [***] and Vendor [***]. If a distributor is not utilized, Vendor will ship the Products to designated CVS regional distribution centers FOB Origin utilizing CVS’s Routing
Guide & Vendor Compliance Instructions, available at www.cvs.suppliers.com, as may be updated by CVS from time to time, subject to acceptance of any material changes by Vendor. 

 

	 	2.2	 Product Allocation and Purchase 

Vendor agrees to sell the Products to CVS, and CVS agrees to purchase the Products from Vendor, subject to the terms and conditions in this
Agreement. 
 LumiraDx commits to make a minimum monthly quantity of the Products available for CVS to purchase as set forth in Exhibit
A, as it may be amended from time to time by mutual agreement of the parties. CVS is not obligated to make any minimum purchases under this Agreement.  

An initial purchase order for Products shall be placed within [***] of receipt by Vendor of the EUA FDA Approval for the SARS-COV antigen test. CVS warrants that it will not utilize any Products purchased prior to Vendor obtaining the necessary EUA FDA Approval. For purposes of this Agreement, “Business Day” means any day
that the New York Stock Exchange is open for trading. 
 Thereafter, [***] prior to the end of each month, CVS shall place a confirmatory
purchase order for the following month identifying the number of LumiraDx Instruments, COVID-19 Test Strips and/or Ancillary Equipment it desires to purchase. If CVS shall fail to place such confirmatory
purchase order, or such order for the LumiraDx Instruments or COVID-19 Test Strips is for quantities less than the monthly allocation listed on Exhibit A, CVS shall not be entitled to such monthly allocation
explicitly tied to such Product type for that month and LumiraDx shall have no obligation to ensure that any shortfall on such purchase order shall roll over and be added to the allocation for the subsequent month. 

Should CVS fail to place any confirmatory purchase order for a consecutive [***] period for the LumiraDx Instruments or the COVID-19 Test Strips, then Vendor and CVS shall adjust the allocation for such Product as set forth on Exhibit A. For the avoidance of doubt and by way of example, CVS’s failure to place a purchase order for
the LumiraDx Instruments shall only extinguish CVS’s entitlement to the corresponding LumiraDx Instruments and shall not modify, remove, nor diminish CVS’s 

 
entitlement to the allocated COVID-19 Test Strips, or vice-versa, as long as such purchase order was placed. CVS shall not be obligated to order or accept
any LumiraDx Instrument where the COVID-19 Test Strip allocation is less than [***] COVID-19 Test Strips per month per LumiraDx Instrument. Vendor may, subject to
availability, make available additional quantities of Products for CVS to purchase, but unless such confirmatory purchase orders are placed timely, Vendor shall not be required to hold such additional monthly quantities for purchase by CVS. 

If Vendor fails to obtain the appropriate and required FDA Approval(s) prior to August 31, 2020, CVS, or its designated distributor on
its behalf, as applicable, retains the right to return any purchased unused Products to Vendor and receive a full refund for any amounts paid to Vendor for such unused Products. 

If at any point during the Term, Vendor fails to maintain the appropriate and required FDA Approval(s), CVS, or its designated distributor on
its behalf, as applicable, retains the right to return any purchased unused Products to Vendor and receive a full refund for any amounts paid to Vendor for such unused Products. If at any point during the Term, any unused COVID-19 Test Strips are delivered to CVS, or its designated distributor on its behalf, with an expiration date of [***] or less, CVS, or its designated distributor on its behalf, as applicable, retains the right to
obtain replacement COVID-19 Test Strips for such COVID-19 Test Strips. 

Each Product’s date of manufacture and expiration, if any, shall be clearly marked at the unit level or smallest quantity grouping for
each Product type. 
  

	3.	 Management Reporting and Communications 

 

	 	3.1	 Vendor Reporting 

Vendor agrees to provide CVS with reports on a monthly basis or as required by CVS, inclusive of but not limited to explanations for any
significant variances or scheduling delays. Vendor may also be required to report other key metrics as defined by additional exhibits to CVS on a monthly basis. Such financial and operational communications shall be provided to CVS in electronic
copies. 
  

	 	3.2	 Communications from CVS to Vendor 

CVS agrees to submit a purchase order to Vendor that specifies the quantity, identification, destination address, and delivery date of the
Products to be ordered. 
 CVS will attempt to provide Vendor with the necessary purchase order numbers and confirmations as far in advance
of the requested shipment arrival date as possible. All orders will be placed by CVS or its designated distributor to the designated associate at Vendor as agreed upon by CVS. 

 

	4.	 Financial Arrangements & Pricing 

 

	 	4.1	 Nature of Financial Arrangements 

Subject to Section 2.1, CVS agrees to pay Vendor at the rates set forth in Exhibit B for the corresponding types of Product and/or
Ancillary Equipment. 

	 	4.2	 Preferred Vendor Status COVID-19 Test Strips: CVS is a preferred
Vendor customer for Products to be used in the United States. Vendor agrees that on a quarterly basis during the Term of this Agreement, it will provide an attestation that, upon information and belief and to the best of its knowledge, as a
preferred Vendor customer, CVS is receiving the best price and is not paying more than any other Vendor customer who is using the COVID-19 Test strips to perform point of care testing in the United States (an
“End User”). End Users do not include purchasers who are a United States Federal or state government agency. If Vendor becomes aware that another End User is receiving better pricing than CVS on purchases of the COVID-19 Test Strips, Vendor will automatically adjust the price of the COVID-19 Test Strips purchased under this Agreement to extend the same pricing to CVS for all future
purchases. Similarly, if CVS provides good faith notice to Vendor that it believes another End User is receiving better pricing, Vendor shall undertake efforts to verify and, if verified, shall extend such pricing to CVS for future purchases. [***]
CVS shall have the right to audit Vendor’s compliance with these obligations pursuant to Section 9. 

  

	 	4.3	 Price Adjustments 

Unless the parties mutually agree in writing to modify Exhibit B, Product prices will be fixed at the rates shown in Exhibit B
so long as this Agreement is in effect except if modified as set forth above in Section 4.2 to provide CVS with the price(s) offered to another Vendor customer. 
  

	 	4.4	 Billing/Monthly Payment Procedures 

Vendor invoices will contain the quantity of each order of Product delivered and the shipping date thereof, applicable unit prices, and any
other information that CVS may from time to time reasonably request hereunder. 
 Products purchased during the first two months from the
date of first purchase order shall be paid pursuant to Vendor’s invoices within [***] from the date of CVS’s receipt of such invoice, other than amounts disputed in good faith. For all subsequent orders and purchases, CVS will pay Vendor
all other amounts due for Products pursuant to Vendor’s invoices within [***] from the date of CVS’s receipt of LumiraDx’s invoice, other than amounts disputed in good faith. In case of
non-payment with regards to Products where there is not a good faith dispute, Vendor shall be entitled to suspend future shipments of Products until payment is made, following a Notice of non-payment which remains uncured. 
 Payment of invoices will not constitute acceptance of Product and
will in no way be considered a waiver of any right of CVS with respect to its remedies hereunder for non-conforming Product or deliveries or other performance or nonperformance by Vendor of its obligations
hereunder or for failure of Vendor to comply with the provisions of this Agreement. Notwithstanding anything in this Agreement to the contrary, CVS’s obligation to pay Vendor shall be conditioned on the prior receipt from Vendor of a complete
and accurate Form W-9 or similar form that is satisfactory to CVS. 

	 	4.5	 Taxes 

The parties’ respective responsibilities for taxes arising under or in connection with this Agreement are as follows: 

Vendor shall separately identify any Transaction Taxes on its invoices (written or electronic) to CVS. CVS agrees to pay any Transaction Taxes
separately identified by Vendor on its invoices, unless CVS provides Vendor with a valid and applicable exemption, direct pay or resale certificate. Any failure by Vendor to charge Transaction Taxes on its invoices shall not result in a liability to
CVS at a later date. For purposes of this Agreement, “Transaction Taxes” mean any sales, use, transaction privilege or any other similar tax, fee or surcharge statutorily imposed by a taxing authority on the sale of products and/or
services by Vendor to CVS pursuant to the terms of this Agreement. 
 Each Vendor invoice shall provide sufficient detail, including without
limitation, location of product delivery or service performance, to support Vendor’s tax treatment of any transaction reflected on an invoice. 

Vendor shall timely file any applicable returns or filings and shall timely remit all Transaction Taxes collected from CVS to the appropriate
taxing authority as required by law. Vendor shall maintain its records, including without limitation, copies of invoices, related documentation and tax returns/filings for a period of not less than [***]. 

Upon written request by CVS, Vendor agrees to provide CVS a list of states, localities, municipalities or other taxing jurisdictions and
corresponding registration numbers for each jurisdiction where Vendor is qualified and registered to do business and collect any Transaction Taxes. If Vendor does not respond in writing to CVS’s request within [***], then CVS shall have the
right, in its sole discretion, to remit the appropriate tax directly to the taxing jurisdiction or withhold payment until the time that such information is provided by Vendor. 

CVS and Vendor agree to cooperate in the audit and minimization of Transaction Taxes in connection with this Agreement. Vendor shall make
available to CVS on a timely basis all information, records, invoices, returns and/or other documentation related to the collection or payment of any Transaction Taxes under this Agreement. 

Vendor agrees that any overpayment of Transaction Taxes by CVS shall be credited or refunded to CVS in a timely manner. 

Vendor shall assume any and all liability for its noncompliance with the terms of this Section, including any interest and penalty assessments
to the extent caused by Vendor’s actions, errors, omissions or inactions. 
 Notwithstanding any provision herein to the contrary, each
party shall be responsible for any income, gross receipts, franchise, corporate excise, payroll, payroll withholding, unemployment or similar types of taxes based on its own income, its own business and for its own employees. 

The provisions of this Section shall survive expiration or termination of this Agreement. 

	5.	 Term and Termination 

 

	 	5.1	 Term 

This Agreement will take effect as of the Effective Date and will continue through December 31, 2021. This Agreement may be renewed or
extended for an additional period of time only by written agreement of the parties. 
  

	 	5.2	 Termination 

For Convenience. CVS may terminate this Agreement without cause upon [***] prior written Notice to the other party. Such written Notice shall
be provided to the parties set forth in Section 12.2 below. 
 For Cause: 

 

	 	(i)	 If either party materially breaches a provision of this Agreement, the other party may give the breaching party
written Notice of such breach. If the breach is not remedied within thirty (30) days thereafter, the party giving Notice shall have the right to terminate this Agreement without further Notice. The rights of termination referred to in this
Section are not intended to be exclusive and are in addition to any other rights and remedies available to either party at law or in equity. 

  

	 	(ii)	 Either party hereto shall have the right to immediately terminate this Agreement and any purchase order for
Products upon written Notice to the other in the event of the other party’s insolvency or receivership; if the other party becomes the debtor in a voluntary or involuntary bankruptcy case; in the event that any part of the other’s property
is or becomes subject to any levy, seizure, assignment or sale from or by a creditor or receiver. 

  

	 	(iii)	 CVS shall have the right to immediately terminate this Agreement and any purchase order for Products upon
written Notice if Vendor fails to obtain and/or maintain any required FDA Approval(s). 

  

	 	5.3	 Effect of Termination 

Upon the effective termination date, all undisputed outstanding amounts shall become due and payable. In the event of termination for any
reason other than Vendor’s breach, Vendor shall provide all ordered Products to CVS within thirty (30) days of the effective termination date. If CVS terminates for cause as set forth above in Section 5.2, CVS may return any unused
Products to Vendor and receive a full refund of any amounts paid. 
 Sections 2, 5, 6, 7, 8, 9, 11, 12.2, and 12.4 shall survive the
expiration or termination of this Agreement. 
  

	6.	 Confidentiality of Data Provided / Non-Publicity

  

	 	6.1	 Confidentiality of Data Provided 

CVS and Vendor will maintain the confidentiality of information shared between the parties in connection with this Agreement in accordance
with the Mutual Non-Disclosure Agreement (“NDA”) between the parties with an effective date of March 23, 2018. 

	 	6.2	 [***] 

  

	 	6.3	 Non-Publicity 

Vendor agrees that neither it nor any of its employees, agents, or subcontractors shall use CVS’s name or any photo or visual or audio
facsimiles of CVS’ facilities or employees for any purpose. Each party agrees that it shall not, and its employees, agents and subcontractors shall not, reveal the nature of the goods and services provided to the other party pursuant hereto, or
any details regarding the goods and services provided pursuant hereto, to any third party for any purpose, unless prior written consent of such other party has been obtained. Vendor shall not use, disseminate, disclose, or publish any work product
or any other materials related to such goods and services in whole or part without prior written consent of CVS. 
  

	7.	 Independent Contractor 

 

	 	7.1	 Independent Contractor 

Vendor shall perform all obligations hereunder as an independent contractor and not as any agent or employee of CVS. Vendor shall make no
representations that it has the authority to bind CVS to any obligation to any third party. 
  

	 	7.2	 [***] 

  

	8.	 Indemnification by Vendor and Insurance 

 

	 	8.1	 Indemnification 

Vendor agrees (i) to indemnify and hold harmless CVS from and against any claims, liabilities and damages to the extent same are due to
Vendor’s negligence, willful misconduct, or breach of this Agreement or Vendor’s failure to comply with or abide by any Applicable Law (other than by reason of an act or omission of CVS), and (ii) to defend promptly and diligently, at
Vendor’s sole expense, with reasonable and documented attorneys’ fees reasonably acceptable to CVS, any claim, action or proceeding brought against CVS or CVS and Vendor jointly or severally, arising out of or connected with any of the
foregoing, and to indemnify and hold CVS harmless from any judgment, loss, or settlement on account thereof. Vendor’s duty to defend CVS under this Section shall apply to any complaint or claim that makes allegations that, if proved, place the
alleged breach of duty, whether in tort or contract, potentially within the purview of the duties, responsibilities and obligations undertaken by Vendor pursuant to this Agreement. 

Vendor agrees to indemnify and defend CVS and any employee or agent thereof against all liability to third parties (other than liability
arising from the actions of CVS or its employees or agents) arising from the violation of any third party’s trade secrets, proprietary information, trademark, copyright, or patent rights in connection with the Products provided hereunder,
regardless of whether CVS provided the specifications for the Products or contributed to the design of the Products to any extent or in any capacity. Vendor shall conduct the defense in any such third party action arising as described herein at its
sole expense and CVS promises to fully cooperate with such defense. 
 The provisions of this Section shall survive the expiration or
termination of this Agreement. 

	 	8.2	 Insurance 

During the term of this contract, Vendor shall, at its expense, carry and maintain: 

 

	 	a)	 Workers Compensation and Employers Liability Insurance meeting minimum statutory requirements,

  

	 	b)	 Commercial Umbrella and/or Employers Liability Limits of no less than [***] each accident for bodily injury and
[***] each employee for bodily injury by disease, 

  

	 	c)	 Commercial General Liability (CGL) and/or Umbrella Liability insurance written on ISO Occurrence form CG 00 01
12 07 or equivalent, with a limit of not less than [***] each occurrence, [***] General Aggregate and [***] Products Completed Operations Aggregate, and 

  

	 	d)	 Automobile Liability and/or Umbrella Liability insurance with limits of not less than [***] each accident.

 The policies shall be underwritten by an insurance company that carries an A-
or better rating from A.M. Best. Each policy (except for Worker’s Compensation) shall provide that: 
  

	 	1.	 CVS Health Corporation and its subsidiaries and affiliates shall be named as additional insureds,

  

	 	2.	 not less than thirty (30) days’ prior written notice shall be given to CVS Health Corporation in the
event of any alteration or terms of such policy or of the cancellation or non-renewal thereof, 

	 	3.	 such insurance (except for Worker’s Compensation) will be primary insurance with respect to CVS Health
Corporation and its subsidiaries and affiliates, and 

  

	 	4.	 Vendor will provide a Waiver of Subrogation against CVS Health Corporation and its agents, officers, directors
and employees for recovery of damages against these policies. 

 Vendor shall furnish CVS Health Corporation with a
Certificate of Insurance evidencing coverage, and a Certificate of Insurance as evidence of renewal at least thirty (30) days prior to expiration of each policy. The amount of such required insurance coverage under this Section shall not limit
Vendor’s obligations under this Agreement. 
  

	9.	 Right to Audit 

CVS, in its sole discretion, shall have the right, but not the obligation, to (i) audit or hire a third party auditor or (ii) allow
(1) state or federal government regulators such as Center for Medicare and Medicaid Services, (2) CVS Pharmacy Benefit Management clients, or (3) accreditation agencies such as URAC, to audit any and all business and operations practices
and procedures of Vendor as they pertain to this Agreement, including, but not limited to, billing practices and procedures. CVS will also have the right to verify / audit the commitments set forth in Section 4.2 are being met via use of an
outside audit company. CVS or its designated agent shall perform any such audits at mutually agreed to times during regular business hours and not more than [***] per year, unless where requested by an external agency. CVS shall provide prior
reasonable notice of an audit to Vendor. Following such audit, CVS may provide a written report of its findings to Vendor, including a timetable for correction of any issues or problems discovered by the auditors. In the event Vendor fails to
correct such issues or problems in a timely manner satisfactory to CVS, this Agreement may be terminated 

 
by CVS for cause in accordance with Section 5.2. Any audit shall be subject to Vendor’s security and confidentiality procedures. Vendor shall be solely responsible for paying the
internal costs and expenses it incurs in connection with an audit conducted under this Section 9 along with any costs and/or expenses associated with any remediation efforts. 

All costs and expenses incurred by CVS for such an audit will be paid by CVS, unless the inspection discloses errors or omissions more than
[***] percent of the invoiced amount in Vendor’s favor in which case the costs and expenses will be paid by Vendor. In the event that an audit discloses any overcharges, the prices will be adjusted to be in accordance with the terms of this
Agreement and the total amount so determined to be overcharged, at CVS’ option, will promptly be credited to the account of CVS or paid to CVS, within thirty (30) days of such finding. 

 

	10.	 Business Continuity 

Vendor shall have a business continuity plan in place to [***]. Vendor shall provide a copy of its business continuity plan to CVS Health
upon written request. Annually, Vendor shall assess and update its business continuity plan in light of current business and technology risks and shall attest to CVS that it has assessed and updated its business continuity plan and capabilities
accordingly. 
  

	11.	 Confirmations, Warranties and Liabilities 

 

	 	11.1	 Vendor shall use commercially reasonable efforts to make the LumiraDx Instrument and COVID-19 Test Strips available for purchase by CVS as soon as the EUA FDA Approval for use in patient care settings outside a clinical laboratory is obtained. If requested by CVS, Vendor shall provide to CVS copies
of the information submitted to the FDA in connection with their application for EUA FDA Approval, any subsequent FDA Approval applications and all correspondence with the FDA. 

 

	 	11.2	 Vendor Warranty: With regards to the LumiraDx Instrument for a period of [***] from date of purchase and
with regards to the COVID-19 Test Strips as per their referenced shelf life, LumiraDx warrants, to CVS, as the original purchaser whether purchased directly or through its designated distributor, that each
Product shall be (i) of good quality and free of material defects, (ii) function in accordance with the material specifications referenced in the Product Insert or Instrument User Manual, and (iii) approved by the proper governmental
agencies required for the sale of products for their intended use (the “limited warranty”). If any Product fails to meet the requirements of the applicable limited warranty, then, LumiraDx shall either repair or replace, at LumiraDx’s
discretion, the LumiraDx Instrument or COVID-19 Test Strips, as applicable. Except for the limited warranty stated in this section, LumiraDx disclaims any and all warranties, express or implied, including but
not limited to, any warranty of merchantability and fitness for a particular purpose regarding the Product. The limited warranty above shall not apply if the customer has subjected the LumiraDx Instrument or
COVID-19 Test Strips to physical abuse, misuse, abnormal use, use inconsistent with the LumiraDx Instrument User Manual or Product Insert, fraud, tampering, unusual physical stress, negligence or accidents.
Unused strips must be stored according to the required storage conditions as printed in this product insert and they can be used only up to the expiry date printed on the Test Strip pouch and Test Strip box. Any warranty claims by CVS pursuant to
the limited warranty shall be made in writing within the 

	 	
applicable limited warranty period. In the event a Product does not conform to the Product Warranty in any respect, Vendor shall, either: (i) accept return of the defective Product and
repair or have repaired the defective Product; or (ii) accept return of the defective Product and provide a replacement Product to CVS. Vendor shall bear the direct costs and expenses of repair and replacement, and Vendor will take all
necessary steps to provide repaired or replacement Products to CVS or its designated distributor. 

  

	 	11.3	 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY OTHER
PERSON OR ENTITY UNDER ANY EQUITY, COMMON LAW, TORT, CONTRACT, ESTOPPEL, NEGLIGENCE, STRICT LIABILITY, OR OTHER THEORY, FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, CONSEQUENTIAL OR CONTINGENT DAMAGES, OR ANY DAMAGES RESULTING FROM LOSS OF SALE,
BUSINESS, PROFITS, DATA, OPPORTUNITY OR GOODWILL, EVEN IF THE REMEDIES PROVIDED FOR IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE, AND EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

The exclusions and limitations of this Section 11.3 do not apply (a) to the extent prohibited by applicable law, (b) to damages
arising in connection with the Vendor’s indemnity obligations set forth in Section 8.1, (c) to breach of either party’s confidentiality obligations, or (d) to damages arising out of either party’s fraud, gross negligence or
willful misconduct. 
  

	12.	 Other Provisions 

 

	 	12.1	 Assignment 

Neither party shall assign, subcontract, or otherwise transfer its rights or obligations under this Agreement except with the prior written
consent of the other, said consent not to be unreasonably withheld; provided, however, either party shall have the right to assign this Agreement to any present or future affiliates, subsidiary, or parent corporation of such party, or pursuant to a
corporate plan of merger, reorganization, or consolidation without securing the consent of Vendor and may grant to any such assignee the same rights and privileges such other party enjoys under this Agreement. Any attempted assignment not assented
to in the manner as prescribed herein, except an assignment confined solely to monies due or to become due, shall be void. 
  

	 	12.2	 Notices 

Any Notice (“Notice”) by either party to the other shall be made by registered or certified mail or by overnight courier
service, provided that a receipt is required, and mailed to the addresses noted below, which may be changed by either party by written Notice to the other party. 

To CVS: 
 CVS Pharmacy, Inc.

 One CVS Drive 
 Woonsocket,
RI 02895 
 Attention: [***] 

 Copy To: [***] 

To Vendor: 
 LumiraDx Inc 

221 Crescent Street 
 Waltham,
MA 02453 
 Attention: CFO 
  

	 	12.3	 Severability 

If any provision of this Agreement or the application thereof to any persons or circumstances shall to any extent be invalid or unenforceable,
the remainder of this Agreement or the application of such provision to persons or circumstances other than those to which it is held invalid or unenforceable shall not be affected thereby, and each provision of this Agreement shall be valid and
enforceable to the fullest extent permitted by law. 
  

	 	12.4	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to the conflict of
law provisions thereof. 
  

	 	12.5	 Compliance with Non-Discrimination and Authorization to Work
Requirements 

 CVS and Vendor shall abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These regulations prohibit discrimination against qualified individuals based on their status
as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, or national origin. Moreover, these regulations require that covered prime contractors and
subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, national origin, protected veteran status or disability. 

 

	 	12.5.1	 Vendor agrees to post in conspicuous places, available for employees and applicants for employment, notices to
be provided by the contracting officer setting forth the provisions of the nondiscrimination clause. 

  

	 	12.5.2	 The parties incorporate into this Agreement, as applicable, the obligations regarding the notice of employee
rights under federal labor laws found at 29 CFR Part 471, Appendix A to Subpart A, and Vendor will likewise incorporate those obligations into all applicable subcontracts as required by 29 CFR Part 471. 

 

	 	12.5.3	 Where Vendor will be providing services, deliverables or other items to CVS pursuant to this Agreement in
connection with federal contracts or subcontracts of $100,000 or more, then CVS and Vendor must file VETS-100A reports by September 30 of each year, or any applicable extension deadline that VETS announces. 41 CFR Part 61-300. 

	 	12.5.4	 Vendor agrees that it will comply with all laws, regulations, and applicable executive orders governing
verification of an employee’s authorization to work in the United States and agrees that it will allow only employees who are authorized to work in the United States to perform work pursuant to this Agreement. 

 

	 	12.5.5	 Vendor certifies that Vendor, its subcontractors and the employees of each are authorized to work in the United
States pursuant to the Immigration Reform and Control Act of 1986 and that such authorization has been verified through Vendor’s or subcontractor’s use of the Department of Homeland Security’s
E-Verify Program, or industry standard equivalent. 

  

	 	12.6	 Debarment and Exclusion 

Each party represents and warrants that neither it, nor any of its employees or agents working on its behalf and providing items and services
pursuant to this Agreement: (i) is currently an Ineligible Person; (ii) has been charged with a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a) or § 1320a-7(b)(l)-(3); or (iii) has been proposed for exclusion, debarment, suspension, or other ineligibility from any Federal health care program or Federal procurement or
non-procurement program. Each party further represents and warrants that if, during the term of this Agreement, it or, with respect to any of its employees or agents working on its behalf and providing items
and services pursuant to this Agreement, it has actual notice that such employee or agent: (i) becomes an Ineligible Person, (ii) is charged with a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a) or § 1320a-7(b)(l)-(3), or (iii) is proposed for exclusion, debarment, suspension, or other ineligibility from any Federal health care program or Federal
procurement or non-procurement program, that party will immediately notify the other party, and such other party will have the right to immediately terminate this Agreement. Vendor agrees to cooperate with any
requests for information by CVS in order to screen Vendor’s employees who are providing items and services pursuant to this Agreement to determine if such employees are Ineligible Persons. Each party agrees to indemnify, defend and hold
harmless, the other party, its officers, directors, shareholders, employees, agents, representatives, affiliates, and assigns (the “Indemnitees”) from any and all liabilities, losses, claims, damages, obligations, costs, and
expenses (including, without limitation, penalties, fines, sanctions, any legal and accounting fees, and expenses, any costs of litigation, investigation, and settlement) that the Indemnitees may incur or suffer as a result of, arising out of, or in
any way connected with (i) such party’s negligence or willful act or omission of any of its obligations under this Section, or (ii) breach by such party of any of its representations and warranties contained in this Section.
“Ineligible Person” means an individual or entity who: (i) is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a), but has not yet been excluded,
debarred, suspended, or otherwise declared ineligible. 
  

	 	12.7	 Entire Agreement 

This Agreement (including all Exhibits) constitutes the entire understanding and Agreement of the parties and supersedes all prior written or
oral agreements with respect to the subject matter in the 

 
Agreement. This Agreement may not be modified or amended unless in writing signed by the parties hereto. Waiver of any provision of the Agreement by a party at any time shall not constitute a
waiver of any other provision of the Agreement, or waiver of the same provision at any other time. 
  

	 	12.8	 Exhibits 

The following Exhibits are incorporated herein by this reference: 

Exhibit A: Product Availability 

Exhibit B: Product Pricing 

Exhibit C: LumiraDx Instrument End User License Agreement 

In the event of any conflict between the terms and conditions found in any Exhibit and the terms and conditions found in the main body of this
Agreement, the terms and conditions found in the main body of this Agreement shall control. 
  

	13.	 Vendor Compliance with CVS Ethical Standards 

CVS requires Vendor (i) to conduct business with CVS in accordance with CVS’s established legal and ethical standards, routines and
procedures (collectively, “Ethical Standards”) and (ii) to refrain from requesting any impermissible favors, allowances or accommodations from CVS or any of its directors, officers, employees or agents. The Ethical Standards, as may
be updated by CVS from time to time, in its sole discretion, can be found at www.cvssuppliers.com. Vendor, at its sole cost and expense, acknowledges and agrees that it shall, as promptly as practicable following the effective date hereof, provide a
copy of the Ethical Standards (and any amendments or restatements thereof) to each of its employees, agents and subcontractors who are responsible for either managing a CVS account or providing products or services to CVS or any affiliate of CVS, in
each such case whether hereunder or otherwise. 
 [THE NEXT PAGE IS THE SIGNATURE PAGE] 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized officers or agents as of
the date first above written. 

									
	CVS Pharmacy, Inc.	 		 	LumiraDx Inc.
					
	By:	 	 /s/ Eva Boratto
	 		 	By:	 	 /s/ Dorian LeBlanc

	Name:	 	Eva Boratto	 		 	Name:	 	Dorian LeBlanc
	Title:	 	EVP & CFO	 		 	Title:	 	Chief Financial Officer
	Date:	 	August 18, 2020	 		 	Date:	 	August 17, 2020

 EXHIBIT A 

PRODUCT AVAILABILITY 
 Subject to Vendor
obtaining appropriate FDA Approvals for the LumiraDx Instrument and COVID-19 Test Strips and the other terms and conditions set forth in the Agreement, CVS shall be entitled to purchase LumiraDx Instruments, COVID-19 Test Strips and Ancillary Equipment in monthly amounts no less than what is outlined below. Failure to order any Product type for a designated month shall mean such Product type is no longer required to be
held by Vendor for supply to CVS for that month and such quantities shall not roll over to the following month. CVS shall not be obligated to order or accept any LumiraDx Instrument where the COVID-19 Test
Strip allocation is less than [***] COVID-19 Test Strips per month per LumiraDx Instrument. 
  

													
	 	  	August	 	September	 	October	 	November	 	December	 	January
	 LumiraDX Instrument Allocation
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Install Base
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 COVID-19 Test Strip Allocation
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
							
	 Strips per Machine, per month
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Strips per Machine, per day
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 [***] 
 [***]. 

[***]. 

 EXHIBIT B 

PRODUCT PRICING 
 Pricing applicable as per
the below list. Pricing for additional products or product combinations or pooling of strips shall be discussed and agreed mutually between the parties based on cost allocation, reimbursement in place and other agreed factors. 

 

							
	 Product
	  	Pack Size	  	Pricing	 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
			
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 

 [***]. 
  

	
	 Products are for professional use (except if specifically
indicated on product otherwise)
  
 LumiraDx and Flame logo are protected trademarks of
LumiraDx. CVS makes no claim to LumiraDx Intellectual Property Rights.
  
 The use of
the LumiraDx Instrument and COVID-19 Test Strips shall be subject to the requirements and specifications as per the Manual, labelling and product specifications. LumiraDx Software for use of the LumiraDx
Instrument is subject to the terms of the End User License Agreement as per attached Exhibit C, which shall apply to CVS and any of its Users (as defined therein). Use of LumiraDx Connect Manager or EHR Connect shall be subject to further license
requirements to be agreed between the Parties.

 EXHIBIT C 

LUMIRADX INSTRUMENT END USER LICENSE AGREEMENT 

PLEASE READ THIS END USER LICENSE AGREEMENT (THIS “AGREEMENT”) BEFORE USING ANY LICENSOR TECHNOLOGY (AS DEFINED BELOW). BY ACCEPTING THIS AGREEMENT,
EITHER BY CLICKING OR TAPPING A BUTTON INDICATING YOUR ACCEPTANCE, EXECUTING AN ORDER FORM OR OTHER DOCUMENT THAT REFERENCES THIS AGREEMENT OR USING ANY LICENSOR TECHNOLOGY, YOU AGREE TO THIS AGREEMENT WITH LUMIRADX UK LTD FOR AND ON BEHALF OF ITS
AFFILIATES (“LICENSOR”). IF YOU ARE ENTERING INTO THIS AGREEMENT ON BEHALF OF A COMPANY OR OTHER LEGAL ENTITY, YOU REPRESENT THAT YOU HAVE THE AUTHORITY TO BIND SUCH ENTITY TO THIS AGREEMENT, IN WHICH CASE THE TERM “CUSTOMER”
WILL REFER TO SUCH ENTITY. IF YOU ARE ENTERING INTO THIS AGREEMENT AS AN INDIVIDUAL, YOU REPRESENT THAT YOU ARE A USER (AS DEFINED BELOW), IN WHICH CASE THE TERM “CUSTOMER” WILL REFER TO YOU AS AN INDIVIDUAL. IF YOU DO NOT HAVE SUCH
AUTHORITY (IF YOU REPRESENT AN ENTITY), OR IF YOU DO NOT AGREE WITH THIS AGREEMENT, YOU MUST NOT ACCEPT THIS AGREEMENT AND MAY NOT USE ANY LICENSOR TECHNOLOGY. 

1.    Definitions. For all purposes of this Agreement, the terms defined below, when used with initial capital letters, will have
the following meanings: 
 (a)     “Documentation” means the physical and electronic documentation provided by
Licensor in conjunction with the Instrument (including the Software). 
 (b)    “Instrument” means the
diagnostic instrument(s) provided by Licensor to Customer. 
 (c)    “Licensor Technology” means the
Instrument (including the Software) and Documentation. 
 (d)    “Patients” means individuals accessing
medical services or care. 
 (e)    “Software” means the proprietary computer software program(s) as embedded
in or installed on the Instrument, and any Updates thereto as delivered to Customer by Licensor under this Agreement, expressly excluding any third party software. 

(f)    “Updates” mean maintenance releases, bug fixes, technological fixes, feature enhancements or
improvements, theme upgrades and other changes made to and entirely new versions of the Software. 

(g)    “Users” means individuals who (i) are 18 years of age or older, (ii) suitably qualified and
trained healthcare professionals and (iii) in the event Customer is an entity, an authorized employee, employee or contractor engaged by an entity managed by Customer, or healthcare professional otherwise engaged by Customer, or, in the event
Customer is an individual, an authorized employee or independent contractor of a purchaser of an Instrument. 
 2.    License
Grant and Restrictions. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Customer a non-exclusive, non-transferable, non-sublicensable limited right and license: to have Users operate the Instrument and Software in accordance with Documentation solely to provide medical services, including medical diagnostics, or care to Patients.
Customer will not and will not permit any third party to: (a) permit any individual other than a User to access or operate the Instrument (including the Software); (b) distribute the Licensor Technology, or any copy thereof, or sublicense or
make it available for use by anyone (other than Users, if Customer is an entity); (c) transfer or sell the Licensor Technology 

 
to any third party; (c) remove, obliterate, obscure, or conceal the proprietary notices or legends which appear on the Licensor Technology; (e) alter, modify, adapt or create derivative
works from the Licensor Technology; (f) decompile, disassemble, translate, or otherwise reverse engineer the Licensor Technology or any part thereof; (g) circumvent any technical limitations of the Licensor Technology or access otherwise
disabled features or functionalities thereof; (h) interfere with the proper working of the Licensor Technology or (i) share or publish the results of any benchmarking or performance testing, and/or compatibility analysis of the Licensor
Technology without Licensor’s prior written consent. 
 3.    Obligations of Customer. 

(a)    Compliance with Laws. Customer will, and if Customer is an entity will cause Users to, comply with all laws
(including federal, state and local laws and regulations, orders and ordinances) now or hereafter enacted, of any jurisdiction in which performance occurs or may occur hereunder. Without limitation, Customer hereby acknowledges that the rights and
obligations of this Agreement are subject to the laws and regulations of the United States relating to the export of products and technical information, and Customer will comply with all such laws and regulations. Customer will not export the
Software under any circumstances. Customer will be solely responsible for its violations of any of the foregoing. 

(b)    Training. The Documentation includes a user manual that provides basic training information for Users.
Customer will implement appropriate controls to ensure that only Users operate the Instrument (including the Software) and that all Users have read and understand the Documentation prior to using the Instrument. Licensor has no obligation to provide
any installation, training, customization, support, maintenance or other services with respect to the Licensor Technology except as may be provided in a separate written agreement signed by a duly authorized officer of Licensor. 

4.    Disclaimers. TO THE FULLEST EXTENT ALLOWED BY LAW, (I) EXCEPT AS SET FORTH IN THE PURCHASE AGREEMENT, LICENSOR DOES NOT
MAKE ANY ADDITIONAL WARRANTIES, WHETHER EXPRESS OR IMPLIED, CONDITIONS, OR REPRESENTATIONS TO CUSTOMER, ANY OF ITS AFFILIATES OR ANY OTHER PARTY WITH RESPECT TO THE LICENSOR TECHNOLOGY OR OTHERWISE REGARDING THIS AGREEMENT, WHETHER ORAL OR WRITTEN,
EXPRESS, IMPLIED, OR STATUTORY; AND (II) THE LICENSOR TECHNOLOGY IS PROVIDED “AS IS” AND “AS AVAILABLE” INCLUDING WITH ALL FAULTS AND ERRORS AS MAY OCCUR THEREIN. WITHOUT LIMITING THE FOREGOING, ANY WARRANTY, CONDITION, OR
REPRESENTATION, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WITH RESPECT TO OPERABILITY, USE, ACCURACY, VALIDITY, MERCHANTABILITY, SATISFACTORY QUALITY, TITLE, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE, ARE EXPRESSLY EXCLUDED AND
DISCLAIMED. LICENSOR DOES NOT WARRANT THAT THE LICENSOR TECHNOLOGY WILL MEET THE CUSTOMER’S REQUIREMENTS OR EXPECTATIONS, OR THAT THE LICENSOR TECHNOLOGY WILL OPERATE UNINTERRUPTED OR ERROR-FREE. THE USE OF THE LICENSOR TECHNOLOGY IS AT THE
SOLE DISCRETION AND RISK OF THE CUSTOMER AND/OR ITS EMPLOYEES, AGENTS, SUBCONTRACTORS, SUCCESSORS, AND ASSIGNS. LICENSOR DOES NOT MAKE ANY WARRANTIES REGARDING THIRD PARTY SOFTWARE (INCLUDING OPEN SOURCE SOFTWARE). CUSTOMER ACKNOWLEDGES AND AGREES
THAT THE TERMS OF A THIRD PARTY SOFTWARE LICENSE MAY OVERRIDE SOME OF THE TERMS OF THIS AGREEMENT. Some states may not allow the exclusion or limitation of warranties, so the above limitation or exclusion may not apply to you. This Agreement gives
Customer specific legal rights and obligations, and Customer may also have other legal rights or obligations which vary from state to state. CUSTOMER ASSUMES SOLE RESPONSIBILITY FOR RESULTS OBTAINED FROM THE USE OF THE LICENSOR TECHNOLOGY AND FOR
CONCLUSIONS DRAWN FROM SUCH USE. CUSTOMER ACKNOWLEDGES THAT THE LICENSOR TECHNOLOGY 

 
WAS NOT DESIGNED TO CUSTOMER’S REQUIREMENTS AND THAT IT IS CUSTOMER’S RESPONSIBILITY TO ENSURE THAT THE LICENSOR TECHNOLOGY AS DESCRIBED IN THE DOCUMENTATION MEETS ITS REQUIREMENTS. THE
LICENSOR TECHNOLOGY IS INTENDED ONLY AS A DIAGNOSTIC AID AND IS NOT A SUBSTITUTE FOR THE EXPERTISE AND JUDGEMENT OF PHYSICIANS OR OTHER HEALTHCARE PROFESSIONALS. ALL INFORMATION IS PROVIDED ON THE BASIS THAT THE HEALTHCARE PROFESSIONALS RESPONSIBLE
FOR PATIENT CARE WILL RETAIN FULL AND SOLE RESPONSIBILITY FOR DECIDING ANY CARE OR TREATMENT TO PRESCRIBE OR DISPENSE FOR ALL PATIENTS AND IN PARTICULAR WHETHER THE USE OF INFORMATION PROVIDED BY THE LICENSOR TECHNOLOGY IS SAFE, APPROPRIATE OR
EFFECTIVE FOR ANY PARTICULAR PATIENT OR IN ANY PARTICULAR CIRCUMSTANCES. 
 5.    Limitation of Liability. LICENSOR’S AND
ITS THIRD-PARTY VENDORS’ MAXIMUM TOTAL LIABILITY FOR ALL MATTERS ARISING UNDER OR RELATED TO THIS AGREEMENT, REGARDLESS OF THE FORM OF ACTION, IN CONTRACT, TORT OR OTHERWISE, WILL NOT EXCEED [***]. IN ANY EVENT, NEITHER LICENSOR NOR ANY OF ITS
THIRD-PARTY VENDORS WILL UNDER ANY CIRCUMSTANCES BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER INDIRECT DAMAGES IN CONNECTION WITH ANY MATTER ARISING UNDER OR RELATED TO THIS AGREEMENT, EVEN IF LICENSOR WAS AWARE OF THE
POSSIBILITY OF SUCH DAMAGES. Some states may not allow the exclusion or limitation of liability or certain damages, so the above limitation or exclusion may not apply to Customer. This Agreement gives Customer specific legal rights and obligations,
and Customer may also have other legal rights or obligations which vary from state to state. 
 6.    Reservation of Rights and
Ownership. The Licensor Technology and all proprietary and intellectual property rights therein are at all times the property of Licensor, and Customer will have no right, title or interest therein except as expressly provided herein. Any rights not
expressly granted in Section 2 above are reserved by Licensor. The Licensor Technology is the proprietary and confidential property of Licensor. Customer will keep confidential the Licensor Technology and will not, and if Customer is an entity
will cause Users not to, use any part of the Licensor Technology in any manner other than as expressly authorized under this Agreement, in accordance with the procedures and guidelines set forth in the Documentation, or otherwise in writing by
Licensor. If Customer is an entity, Customer is liable for any of its User’s breach or non-compliance. 

7.    Term and Termination. The Licensor Technology is licensed to Customer during the time the Instruments are used by Customer,
subject to termination as set forth herein. Licensor may terminate this Agreement in whole or in part by written notice to Customer, in the event of the occurrence of any of the following: (a) if Customer, or if Customer is an entity any of its
Users, uses, reproduces, distributes or sublicenses, as applicable, any of the Licensor Technology in any manner not authorized herein; (b) if Customer or any of its Users (if applicable) transfers or allows any third party (other than such
Users) to access or operate any Instrument without Licensor’s prior written consent; (c) if Customer or any of its Users (if applicable) breaches this Agreement (other than as set forth in the foregoing clauses (a) or (b)) and does
not cure such breach within 14 days after written demand by Licensor; or (iv) if Customer makes a general assignment for the benefit of creditors, or files a voluntary petition in bankruptcy or for reorganization or arrangement under the
bankruptcy laws, or if a petition in bankruptcy is filed against Customer and is not dismissed within 30 days after the filing, or if a receiver or trustee is appointed for all or any part of the property or assets of Customer. Upon any termination
of this Agreement the license granted under this Agreement will terminate, and Customer will immediately (i) cease all use of the Licensed Technology, (ii) destroy all copies of the Documentation and (iii) delete or remove all patient
data or other personal data from the Software. Upon such termination, all rights and obligations of the parties under this Agreement will cease except that the provisions of Sections 4 through 8 (inclusive) will survive. 

 8.    General. Customer may not assign this Agreement, or sublicense any of the
rights granted herein, in whole or in part, without the prior written consent of Licensor, which consent may be withheld at the sole discretion of Licensor. Any attempted assignment, delegation or transfer in violation hereof will be null and void.
Subject to the foregoing, this Agreement will be binding on the parties and their successors and assigns. This Agreement contains the entire understanding of the parties about its subject. It supersedes and replaces all prior or contemporaneous
understandings or agreements, written or oral, regarding such subject matter, and prevails over any conflicting terms or conditions contained on printed forms submitted with purchase orders, sales acknowledgments or quotations. No provision or part
of this Agreement or remedy hereunder may be waived except by a writing signed by a duly authorized representative of the party making the waiver. Any such waiver will be narrowly construed to apply only to the specific provision and under the
specific circumstances for which it was given, and will not apply with respect to any repeated or continued violation of the same provision or any other provision. Failure or delay by either party to enforce any provision of this Agreement will not
be deemed a waiver of future enforcement of that or any other provision. Nothing in this Agreement will be construed to place Licensor and Customer in an agency, employment, franchise, joint venture, or partnership relationship. Neither party will
have the authority to obligate or bind the other in any manner, and nothing herein contained will give rise or is intended to give rise to any rights of any kind to any third parties. Neither party will represent to the contrary, either expressly,
implicitly or otherwise. In the event that any provision of this Agreement is found to be unenforceable, such provision will be reformed only to the extent necessary to make it enforceable, and such provision as so reformed will continue in effect,
to the extent consistent with the intent of the parties as of the effective date hereof. If any provision or part of this Agreement will, to any extent, be or become invalid, illegal or unenforceable, the remainder of this Agreement will continue in
effect, and every other provision of this Agreement will remain valid and enforceable to the full extent permitted by applicable law. In such event, the invalid or unenforceable provision will be reformed only to the extent necessary to make it
enforceable, and such provision as so reformed will continue in effect, to the extent consistent with the intent of the parties as of the effective date hereof. This Agreement is made under and will be governed by and construed in accordance with
the laws of the State of New York, without regard to its conflict of laws principles, and specifically excluding from application to this Agreement the United Nations Convention on the International Sale of Goods.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]